Phase IIB TL + YCWP + DC in Melanoma

PHASE2CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 11, 2022

Study Completion Date

May 11, 2022

Conditions
Melanoma
Interventions
DRUG

TLPLDC

Autologous tumor lysate, particle-loaded dendritic cell vaccine

DRUG

Placebo

Trial Locations (18)

10016

Laura and Isaac Permutter Cancer Center @ NYU Langone, New York

19107

Thomas Jefferson University, Philadelphia

29607

St. Francis Hospital Cancer Center, Greenville

30341

Northside Hospital Cancer Institute, Atlanta

33140

Mount Sinai Cancer Research Program, Miami Beach

35243

University of Alabama Birmingham (UAB) Comprehensive Cancer Center, Birmingham

43202

The Ohio State University Comprehensive Cancer Center, Columbus

45267

University of Cincinnati Cancer Institute, Cincinnati

46601

Memorial Hospital of South Bend, South Bend

55905

Mayo Clinic, Rochester, Rochester

60611

Northwestern Memorial Hospital, Chicago

84112

Huntsman Cancer Institute/The University of Utah, Salt Lake City

85054

Mayo Clinic - Cancer Clinical Research Office, Phoenix

85724

The University of Arizona Cancer Center, Tucson

87102

New Mexico Cancer Care Alliance, Albuquerque

90025

The Angeles Clinic and Research Institute A Cedars-Sinai Affiliate, Los Angeles

90404

John Wayne Cancer Institute, Santa Monica

98201

Providence Regional Medical Center Everett, Everett

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

LumaBridge

INDUSTRY

lead

Elios Therapeutics, LLC

INDUSTRY

NCT02301611 - Phase IIB TL + YCWP + DC in Melanoma | Biotech Hunter | Biotech Hunter